UNLOXCYT long-term data to be presented at ESMO 2026
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty 100 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma will present long-term data from a 205-patient study of UNLOXCYT in advanced skin cancer at ESMO on October 24. Response rates were 44.4% to 53.1%, with complete responses of 16.7% to 34.4%. Among responders, 68.6% to 81.8% were estimated to remain in response at two years. Grade 3 immune-related adverse events occurred in 2.9%; no grade 4 events or related deaths were reported. UNLOXCYT was approved by US FDA in 2024.
The data may support investor confidence in UNLOXCYT, but no new approval, revenue guidance or financial forecast was announced.